Login to Your Account

Actelion Adding PAH Power With $420M CoTherix Buyout

By Cormac Sheridan

Tuesday, November 21, 2006
Broadening its footprint in its key market of pulmonary arterial hypertension (PAH), while reducing its dependence on its Tracleer (bosentan) franchise, Actelion Ltd. entered a definitive agreement to acquire CoTherix Inc. for $13.50 per share, or about $420 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription